China Headquarters

US Division

NEWS CENTER

Get to know Biosion in real time

>
>
Biosion, Inc. Appoints Hugh Davis, Ph.D., Chief Operating Officer and President of Biosion USA, Inc.

Biosion, Inc. Appoints Hugh Davis, Ph.D., Chief Operating Officer and President of Biosion USA, Inc.

[Abstract]:
Biosion,Inc.AppointsHughDavis,Ph.D.,ChiefOperatingOfficerandPresidentofBiosionUSA,Inc.NEWARK,Delaware,andNANJING,China. March23,2020–BiosionInc.,announcedtheappointmentofHughM.Davis,Ph.D.,asChiefOpera

 

 

Biosion, Inc. Appoints Hugh Davis, Ph.D., Chief Operating Officer and President of Biosion USA, Inc.

NEWARK, Delaware, and NANJING, China. March 23, 2020 – Biosion Inc., announced the appointment of Hugh M. Davis, Ph.D., as Chief Operating Officer, Biosion, Inc. and President of Biosion USA, Inc.  Dr. Davis joins Biosion from Frontage Laboratories, Inc., where he served as Chief Business Officer.

“We are pleased to welcome Hugh to the executive team and Board of Directors of Biosion. Hugh brings a tremendous wealth of industry experience in biologics research & development and across the biopharmaceutical value chain, including both strategy and execution,” said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion, Inc. “Based on our proprietary antibody discovery platform and SynAb™ technology, Biosion has built an innovative biotherapeutics portfolio to address key unmet medical needs of patients with immune and oncology-related diseases. Hugh will be integral to developing and driving portfolio and corporate strategy for the next stage of our growth. He will also oversee our global business operations and clinical development of our innovative therapeutics portfolio.”

Dr. Davis is a seasoned executive with over 30 years of experience in the development of biologics therapeutics. At Janssen R &D/Johnson & Johnson, Hugh was Vice President & Head, Biologics Development Sciences, Biophysics and Laboratory Operations. He and his team were instrumental in the development and approval of many biologic therapies including Remicade®, Stelara®, Simponi®, Sylvant®, Tremfya® and Darzalex®.  Following his tenure at Janssen R&D, Hugh joined Frontage Laboratories, Inc. as Chief Business Officer, where he played a critical role in leading the company to a very successful IPO in May of 2019. Dr. Davis holds a Ph.D. in Biochemistry from Villanova University, Villanova, PA, USA.

About Biosion, Inc.

Biosion, Inc. is a global biotechnology company, discovering and developing innovative therapeutics for oncology and immunological diseases. Leveraging our proprietary H³ (High-throughput, High-content, High-efficiency) antibody platform and SynAb™ technology, the company is committed to discovering and developing innovative biologics for patients with unmet medical needs. The company is building a proprietary therapeutic pipeline through its innovative internal discovery efforts and through co-development programs in collaboration with biotech and pharmaceutical companies. For more information, visit www.biosion.com

 

Contacts:

 

Shengmei Ma

Biosion USA, Inc.

Newark, DE

+1-508-410-6008

shengmei.ma@biosion.com

 

Ailie Su

Biosion, Inc.

Nanjing, China

+86-199-5241-5530

ailie.su@biosion.com